Shijiazhuang Yiling Pharmaceutical‘s patent involves a compound with potent GnRHR antagonist activity similar to Elagolix, with improved pharmacokinetic properties. The compound’s chemical structure is detailed in Formula I. GlobalData’s report on Shijiazhuang Yiling Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shijiazhuang Yiling Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Shijiazhuang Yiling Pharmaceutical's grant share as of February 2024 was 63%. Grant share is based on the ratio of number of grants to total number of patents.
Gnrhr antagonist compound with improved pharmacokinetic properties
A recently granted patent (Publication Number: US11884636B2) discloses a compound and its various forms, including salts, isomers, prodrugs, polymorphs, and solvates, with a specific chemical structural formula outlined in Formula I. The patent also details a method for preparing this compound through hydrolysis, with the process involving the use of a base. Furthermore, the patent describes a method for preparing a drug to treat gonadal hormone-related diseases by combining the compound with suitable excipients, particularly emphasizing the use of a gonadotropin-releasing hormone receptor antagonist as the drug.
Moreover, the patent highlights the wide range of gonadal hormone-related diseases that can be targeted using the disclosed drug preparation method, including conditions such as endometriosis, amenorrhea, menstrual irregularity, hysteromyoma, and various others. Additionally, the patent specifies the potential application of the drug composition in treating gonadotropin-dependent tumors like prostate cancer, uterine cancer, breast cancer, ovarian cancer, and pituitary gonadotropic adenomas. Overall, the patent provides a comprehensive overview of the compound, its preparation method, and its potential therapeutic uses in addressing a diverse array of gonadal hormone-related diseases and tumors.
To know more about GlobalData’s detailed insights on Shijiazhuang Yiling Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
